Kathleen Pishas

Kathleen Pishas
Adelaide Medical School
Faculty of Health and Medical Sciences

Connect With Me

Kathleen Pishas

Awards and Achievements

Date Type Title Institution Name Amount
2017 - 2018 Cancer Free Kids Grant
2016 NHMRC CJ Martin Overseas Biomedical Early Career Fellowship
2016 - 2019 Alex's Lemonade Stand Young Investigator Grant
2014 PhD Research Excellence Award (Health and Medical Science)
2014 Best Poster Presentation
2013 Postdoctoral Clinical Cancer Research Fellowship University of Adelaide
2013 Ross Wishart Memorial Award
2013 Dean’s Commendation for Doctoral Thesis Excellence University of Adelaide
2012 Outstanding Poster Presentation
2012 Trevor Prescott Memorial Scholarship Freemasons Foundation
2010 - 2013 Australian Postgraduate Award
2010 Florey Medical Research Foundation Postgraduate Top Up Cancer Research Scholarship University of Adelaide
2009 Jemima Lendrum Prize for Cancer Research

Education

Date Institution name Country Title
2010 - 2013 Univserity of Adelaide Australia PhD in Medicine
University of Adelaide Australia Bachelor of Biomedical Science, Bachelor of Health Science (Honours)

Journals

Date Citation
2017 Shakya,R, Tarulli,G, Sheng,L, Lokman,N, Ricciardelli,C, Pishas,K, Selinger,C, Kohonen-Corish,M, Cooper,W, Turner,A et al, 2017, Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer, Oncogene, - 10.1038/onc.2017.66
2016 Sheng,L, Anderson,P, Turner,A, Pishas,K, Dhatrak,D, Gill,P, Morris,H, Callen,D, 2016, Identification of vitamin D3 target genes in human breast cancer tissue, Journal of Steroid Biochemistry and Molecular Biology, 164, 90-97 10.1016/j.jsbmb.2015.10.012
2016 Theisen,E, Pishas,K, Saund,R, Lessnick,S, 2016, Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting, Oncotarget, 7, 14, 17616-17630 10.18632/oncotarget.7124
2016 Pishas,K, Lessnick,S, 2016, Recent advances in targeted therapy for Ewing sarcoma, F1000Research, 5, 2077-2077 10.12688/F1000RESEARCH.8631.1
2015 Pishas,K, Adwal,A, Neuhaus,S, Clayer,M, Farshid,G, Staudacher,A, Callen,D, 2015, Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma (Scientific Reports (2015) 5:11465) doi: 10.1038/srep11465), Scientific Reports, 5, - 10.1038/srep13328
2015 Pishas,K, Adwal,A, Neuhaus,S, Clayer,M, Farshid,G, Staudacher,A, Callen,D, 2015, XI-006 induces potent p53-independent apoptosis in Ewing sarcoma, Scientific Reports, 5, 11465-1-11465-16 10.1038/srep11465
2014 Pishas,K, Neuhaus,S, Clayer,M, Schreiber,A, Lawrence,D, Perugini,M, Whitfield,R, Farshid,G, Manavis,J, Chryssidis,S et al, 2014, Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling, Cancer Research, 74, 3, 921-931 10.1158/0008-5472.CAN-13-2424
2013 Pishas,K, Neuhaus,S, Clayer,M, Adwal,A, Brown,M, Evdokiou,A, Callen,D, Neilsen,P, 2013, Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy, Oncology Reports, 30, 1, 471-477 10.3892/or.2013.2454
2013 Neilsen,P, Pehere,A, Pishas,K, Callen,D, Abell,A, 2013, New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity, ACS Chemical Biology, 8, 2, 353-359 10.1021/cb300549d
2012 Suetani,R, Ho,K, Jindal,S, Manavis,J, Neilsen,P, Pishas,K, Rippy,E, Bochner,M, Kollias,J, Gill,P et al, 2012, A comparison of vitamin D activity in paired non-malignant and malignant human breast tissues, Molecular and Cellular Endocrinology, 362, 1-2, 202-210 10.1016/j.mce.2012.06.022
2011 Neilsen,P, Pishas,K, Callen,D, Thomas,D, 2011, Targeting the p53 pathway in Ewing Sarcoma, Sarcoma, 2011, 746939-1-746939-17 10.1155/2011/746939
2011 Pishas,K, Al-ejeh,F, Zinonos,I, Kumar,R, Evdokiou,A, Brown,M, Callen,D, Neilsen,P, 2011, Nutlin-3a is a potential therapeutic for Ewing sarcoma, Clinical Cancer Research, 17, 3, 494-504 10.1158/1078-0432.CCR-10-1587

Conference Items

Date Citation
2013 Mayo,B, Bateman,E, Stringer,A, Plews,E, Pishas,K, Pietra,C, Cantoreggi,S, Keefe,D, 2013, The effect of the new selective GLP-2 agonist, Elsiglutide, on irinotecan-induced diarrhoea and mucositis in the rat., Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) symposium, Berlin, Germany 10.1007/s00520-013-1798-3
2013 Mayo,B, Bateman,E, Stringer,A, Plews,E, Pishas,K, Pietra,C, Cantoreggi,S, Yazbek,R, Keefe,D, 2013, The effect of the new selective GLP-2 agonist, elsiglutide, on irinotecan-induced diarrhoea and mucositis in the rat, Clinical Oncology Society of Australia 40th Annual Scientific Meeting, Adelaide Convention Centre, Adelaide, South Australia 10.1111/ajco.12144

Memberships

Date Role Membership Country
2013 Member Australasian Sarcoma Study Group Australia
Org Unit
Medical Specialties

top